InMedica bonds are offered to private and institutional investors, who will receive an annual interest rate of 5%. The issue is launched to refinance the previous issue of 5 million euros. The remaining funds will be used to finance the acquisition of new clinics and organic development. “Even though the pandemic has brought a lot of uncertainty to the market, we clearly see growing potential in the healthcare sector. This led to the decision to pursue ambitious expansion plans and develop new projects that require additional investment. We value investors. “trust and we are convinced that by investing new funds effectively, we will be able to create value for all stakeholders: bond investors, our shareholders and, of course, patients”, said Kęstutis Broniukaitis, CEO of InMedica. According to the CEO of InMedica, the pandemic has highlighted the growing demand for medical services, which opens up new development opportunities for medical institutions. “At the moment, InMedica’s main objective is to improve the quality and accessibility of the services provided to patients; therefore, the funds will be used to develop new clinics, purchase modern equipment and attract the most professional specialists. This will allow us to constantly increase the efficiency of our clinics and succeed in adapting to changes dictated by the market, ”said Mr. Broniukaitis. According to Domas Klimavičius, head of the investment services group of Šiaulių bankas – the distributor of the bonds – “This is the issuer’s second bond issue. The successful first distribution has boosted investor confidence and as a result , interest in bonds from this network of medical clinics is high. It should be noted that the local bond market is dominated by players in the real estate sector, which makes InMedica’s bond title an excellent tool for diversifying a portfolio. bond. ”In total, investors can buy up to 80,000 units of corporate bonds. The face value of a bond is 100 EUR. From 8 Decembere, 2021, the public bond issue of the company is distributed by Šiaulių bankas. The end of the distribution is set for December 16, 2021e at 12 p.m. GMT + 2. Newly issued securities will be included in the alternative stock market First North, administered by the Nasdaq Vilnius. Sorainen & Partners has been selected as a certified bond advisor.
About InMedica With a network of 34 clinics in several cities, InMedica is one of the largest private medical centers in Lithuania. InMedica provides diagnostic, outpatient, surgical, dental and other medical services. The InMedica group consists of 21 family medicine centers, 4 high profile clinics, 1 clinic specializing in cardiology, 6 walk-in clinics and 3 laboratories. The InMedica group has over 1,000 employees and provides healthcare services to over 100,000 registered patients. In 2020, the Group achieved sales of 18.0 million euros. As of February 2019, 70% of InMedica shares have been held by INVL Baltic Sea Growth Fund, one of the largest private equity funds in the Baltic States, through its subsidiary BSGF Sanus.
About INVL Baltic Sea Growth Fund INVL Baltic Sea Growth Fund, with a total size of EUR 165 million, is one of the largest private equity funds in the Baltic States, with the European Investment Fund (EIF) being its lead investor. The EIF, which is part of the European Investment Bank, has committed € 30 million with support from the European Fund for Strategic Investments, a key part of the Investment Plan for Europe (or “Junker Plan” ), as well as the allocation of resources from the Baltic Innovation Fund, the “fund of funds” initiative developed in cooperation with the governments of Lithuania, Latvia and Estonia. This aims to increase capital investment in small and medium-sized enterprises with high growth potential in the Baltic States. The Fund seeks to build a diversified portfolio of companies, targeting transactions with significant majority or minority holdings and writing tickets of 10 to 30 million euros, which exhibit high growth potential and the ability to compete on a genuinely global. The Fund focuses on the Baltic States and the neighboring regions of Poland, Scandinavia and Central Europe in particular. So far, the Fund has invested in four companies in the healthcare, civil engineering and environmental management sectors (plastic recycling and waste management) respectively. The Fund is managed by one of the leading Lithuanian asset management companies, INVL Asset Management, which is part of the Invalda INVL group. Group companies manage pension funds and mutual funds, alternative investments, individual portfolios, private equity assets and other financial instruments. More than 200,000 clients in Lithuania and Latvia and international investors at the end of 2019 entrusted the group with more than € 1.5 billion in assets under management. Active since 1991 and with a solid background, Invalda INVL has 30 years of experience in managing private equity assets in the Baltic States and the Central and Eastern European landscape while developing businesses into first-rate market leaders.
More information: Kęstutis Broniukaitis CEO of InMedica Tel. +370 618 19174 E-mail: [email protected]
The network of medical clinics InMedica has launched a new bond distribution, during which it will seek to borrow up to 8 million euros for a period of 2 years.
2021-12-09